Laura Sanchez-Cenizo
Overview
Explore the profile of Laura Sanchez-Cenizo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fajardo C, Alvarez-Escola C, Biagetti B, Garcia-Centeno R, Ciriza R, Sanchez-Cenizo L, et al.
Endocrine
. 2023 Jul;
82(2):379-389.
PMID: 37507554
Objective: Acromegaly is a rare disease caused by increased growth hormone secretion and a subsequent increase in insulin-like growth factor I (IGF-I) levels. Patients display multiple comorbidities that affect their...
2.
Marazuela M, Blanco C, Bernabeu I, Menendez E, Villar R, Paja M, et al.
Endocrine
. 2021 Oct;
75(2):525-536.
PMID: 34668173
Objectives: To evaluate disease activity status using the Acromegaly Disease Activity Tool (ACRODAT) in a cohort of Spanish acromegaly patients, to assess the relationship between the level of disease activity...
3.
Labarta J, de Arriba A, Ferrer M, Loranca M, Martos J, Rodriguez A, et al.
J Pediatr Endocrinol Metab
. 2020 Jul;
33(7):923-932.
PMID: 32623373
Objectives To study the efficacy and influence on metabolism of recombinant human growth hormone (rhGH) treatment in short children born small for gestational age (SGA). Methods Retrospective, observational, multicenter study...
4.
Sanchez-Cenizo L, Aller J, Martinez-Sesmero J, Mir N, Peral C, Rubio-Rodriguez D, et al.
Clinicoecon Outcomes Res
. 2019 Aug;
11:465-475.
PMID: 31413609
Objective: To evaluate the burden of diabetes mellitus (DM) in adult patients with acromegaly treated with second-line pharmacotherapy, from the perspective of the Spanish National Health System (NHS). Methods: A...
5.
Peral C, Cordido F, Gimeno-Ballester V, Mir N, Sanchez-Cenizo L, Rubio-Rodriguez D, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2019 May;
20(1):105-114.
PMID: 31055976
: To estimate the cost-effectiveness of second-line pharmacological treatments in patients with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish National Health System (NHS) perspective.: A Markov...
6.
Camara R, Venegas E, Garcia-Arnes J, Cordido F, Aller J, Samaniego M, et al.
Pituitary
. 2019 Feb;
22(2):137-145.
PMID: 30756345
Purpose: The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly...
7.
Santacatterina F, Sanchez-Cenizo L, Formentini L, Mobasher M, Casas E, Rueda C, et al.
Oncotarget
. 2015 Nov;
7(1):490-508.
PMID: 26595676
The ATPase Inhibitory Factor 1 (IF1) is an inhibitor of the mitochondrial H+-ATP synthase that regulates the activity of both oxidative phosphorylation (OXPHOS) and cell death. Here, we have developed...
8.
Formentini L, Pereira M, Sanchez-Cenizo L, Santacatterina F, Lucas J, Navarro C, et al.
EMBO J
. 2014 Feb;
33(7):762-78.
PMID: 24521670
A key transducer in energy conservation and signaling cell death is the mitochondrial H(+)-ATP synthase. The expression of the ATPase inhibitory factor 1 (IF1) is a strategy used by cancer...
9.
Formentini L, Sanchez-Arago M, Sanchez-Cenizo L, Cuezva J
Mol Cell
. 2012 Feb;
45(6):731-42.
PMID: 22342343
Recent findings indicate that prevalent human carcinomas overexpress the mitochondrial ATPase Inhibitory Factor 1 (IF1). Overexpression of IF1 inhibits the synthase activity of the mitochondrial H(+)-ATP synthase and plays a...
10.
Sanchez-Cenizo L, Formentini L, Aldea M, Ortega A, Garcia-Huerta P, Sanchez-Arago M, et al.
J Biol Chem
. 2010 Jun;
285(33):25308-13.
PMID: 20538613
The H(+)-ATP synthase is a reversible engine of mitochondria that synthesizes or hydrolyzes ATP upon changes in cell physiology. ATP synthase dysfunction is involved in the onset and progression of...